These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34542933)

  • 1. Biomarkers for the clinical development of antiviral therapies.
    Ng TI; Dorr PK; Krishnan P; Cohen DE; Rhee S; Wang SX; Ruzek MC; Mensa FJ; Kati WM
    Cytometry B Clin Cytom; 2021 Jan; 100(1):19-32. PubMed ID: 34542933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitric Oxide to Fight Viral Infections.
    Lisi F; Zelikin AN; Chandrawati R
    Adv Sci (Weinh); 2021 Apr; 8(7):2003895. PubMed ID: 33850691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad-Spectrum Antiviral Agents Based on Multivalent Inhibitors of Viral Infectivity.
    Zelikin AN; Stellacci F
    Adv Healthc Mater; 2021 Mar; 10(6):e2001433. PubMed ID: 33491915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug combination therapy for emerging viral diseases.
    Shyr ZA; Cheng YS; Lo DC; Zheng W
    Drug Discov Today; 2021 Oct; 26(10):2367-2376. PubMed ID: 34023496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human coronaviruses and therapeutic drug discovery.
    Song LG; Xie QX; Lao HL; Lv ZY
    Infect Dis Poverty; 2021 Mar; 10(1):28. PubMed ID: 33726861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stopping pandemics before they start: Lessons learned from SARS-CoV-2.
    Edwards AM; Baric RS; Saphire EO; Ulmer JB
    Science; 2022 Mar; 375(6585):1133-1139. PubMed ID: 35271333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses.
    Zheng Y; Li S; Song K; Ye J; Li W; Zhong Y; Feng Z; Liang S; Cai Z; Xu K
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Tracking of Antiviral Drug Combinations.
    Ianevski A; Yao R; Biza S; Zusinaite E; Mannik A; Kivi G; Planken A; Kurg K; Tombak EM; Ustav M; Shtaida N; Kulesskiy E; Jo E; Yang J; Lysvand H; Løseth K; Oksenych V; Aas PA; Tenson T; Vitkauskienė A; Windisch MP; Fenstad MH; Nordbø SA; Ustav M; Bjørås M; Kainov DE
    Viruses; 2020 Oct; 12(10):. PubMed ID: 33080984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virus-Host Interactions: New Insights and Advances in Drug Development Against Viral Pathogens.
    Prasad M; Ranjan K; Brar B; Shah I; Lalmbe U; Manimegalai J; Vashisht B; Gaury M; Kumar P; Khurana SK; Prasad G; Rawat J; Yadav V; Kumar S; Rao R
    Curr Drug Metab; 2017; 18(10):942-970. PubMed ID: 28952435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics.
    Gutierrez-Chamorro L; Felip E; Ezeonwumelu IJ; Margelí M; Ballana E
    Trends Microbiol; 2021 Sep; 29(9):836-848. PubMed ID: 33618979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The global succinylation of SARS-CoV-2-infected host cells reveals drug targets.
    Liu Q; Wang H; Zhang H; Sui L; Li L; Xu W; Du S; Hao P; Jiang Y; Chen J; Qu X; Tian M; Zhao Y; Guo X; Wang X; Song W; Song G; Wei Z; Hou Z; Wang G; Sun M; Li X; Lu H; Zhuang X; Jin N; Zhao Y; Li C; Liao M
    Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2123065119. PubMed ID: 35858407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral Drug Discovery To Address the COVID-19 Pandemic.
    Richman DD
    mBio; 2020 Sep; 11(5):. PubMed ID: 32978312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Covalent Antiviral Agents.
    Mirzaie S; Abdi F; GhavamiNejad A; Lu B; Wu XY
    Adv Exp Med Biol; 2021; 1322():285-312. PubMed ID: 34258745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molnupiravir and Its Antiviral Activity Against COVID-19.
    Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
    Front Immunol; 2022; 13():855496. PubMed ID: 35444647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral therapies: advances and perspectives.
    Gonçalves BC; Lopes Barbosa MG; Silva Olak AP; Belebecha Terezo N; Nishi L; Watanabe MA; Marinello P; Zendrini Rechenchoski D; Dejato Rocha SP; Faccin-Galhardi LC
    Fundam Clin Pharmacol; 2021 Apr; 35(2):305-320. PubMed ID: 33011993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.